During the past 12 months, Joinn Laboratories (China) Co's average Book Value Per Share Growth Rate was 1.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 56.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 49.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Joinn Laboratories (China) Co was 108.30% per year. The lowest was 4.10% per year. And the median was 33.60% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Joinn Laboratories (China) Co Book Value per Share Chart
Competitive Comparison of Joinn Laboratories (China) Co's Book Value per Share
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Joinn Laboratories (China) Co (SHSE:603127) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Joinn Laboratories (China) Co Book Value per Share Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603127 has been successfully added to your 